Opexa is developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS).
Opexa president and chief executive officer Neil Warma said they are pleased with the depth of PRA’s experience along with their insights into the industry.
"We are confident that this collaboration with PRA’s top-notch clinical management team will provide Opexa superior support to accumulate and report the data from this study in an efficient and cost effective manner,"Warma added.
PRA business development senior vice president Tami Klerr-Naivar said the company will support the upcoming planned Phase IIb clinical trial of Tovaxin.